The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KYTX | +44.62% | N/A | N/A | -75% |
| S&P | +13% | +86.41% | +13.26% | +35% |
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.42M | 25.6% |
| Market Cap | $259.47M | 23.0% |
| Market Cap / Employee | $2.01M | 0.0% |
| Employees | 129 | 0.0% |
| Net Income | -$36.79M | -6.7% |
| EBITDA | -$38.31M | -0.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $34.16M | -67.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.34M | -74.3% |
| Short Term Debt | $3.69M | -6.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -61.17% | 0.0% |
| Return On Invested Capital | -61.98% | 5.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$43.71M | -58.4% |
| Operating Free Cash Flow | -$43.32M | -57.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.53 | 0.31 | 0.59 | 1.41 | 122.46% |
| Price to Tangible Book Value | 0.53 | 0.31 | 0.59 | 1.41 | 122.46% |
| Enterprise Value to EBITDA | 2.87 | 3.25 | 1.66 | -2.46 | -192.87% |
| Return on Equity | -80.7% | -49.7% | -61.3% | -70.8% | - |
| Total Debt | $8.24M | $6.94M | $5.92M | $5.02M | -45.01% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
